Secondary Prophylaxis with Low Molecular Weight Heparin: The Dose?

Thromb Haemost 2001; 86(04): 1129
DOI: 10.1055/s-0037-1616552

Letters to the Editor

Schattauer GmbH

Authors

McDonald K. Horne

¹Hematology Service, Department of Laboratory Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA

References
1 Hull R, Delmore T, Carter C. et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-94.
2 Hommes DW, Bura A, Mazzolai L. et al. Subcutaneous heparin compared with continuous intravenous heparin administered in the initial treatment of deep venous thrombosis. Ann Intern Med 1992; 116: 279-284.
3 Lopaciuk S, Bielska-Falda H, Noszczyk W. et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999; 81: 26-31.
4 Pini M, Aiello S, Manotti C. et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72: 191-7.
5 Veiga F, Escriba A, Maluenda MP. et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 2000; 84: 559-64.
6 Das SK, Cohen AT, Edmondson RA. et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996; 20: 521-7.
7 Harenberg J, Huhle G, Piazolo L. et al. Long-term anticoagulation of out-patients with adverse events to oral anticoagulants using low-molecular-weight heparin. Semin Thromb Hemost 1997; 23: 167-72.